OmniAb, Inc.
Key statistics
from XBRL data in SEC filingsAI briefing
from the latest 10-K, 10-Q and 8-K eventsOmniAb, Inc. is an antibody discovery technology licensing company that provides transgenic animal platforms and AI-powered screening tools to pharmaceutical and biotech partners.
What they do
OmniAb licenses its discovery technology to partners, offering proprietary transgenic animals (OmniRat, OmniChicken, OmniMouse, OmniFlic, OmniClic, OmniTaur, Omni dAb, OmniUltra) and in silico AI/ML tools (OmniDeep) plus the xPloration high-throughput B-cell screening platform. Revenue comes from platform access fees, service revenue (including ion channel programs), milestones, royalties, and xPloration instrument and consumable sales.
Revenue drivers
- Milestone revenue — Drove the Q2 2026 revenue increase to $13.4M; milestone payments are tied to partner program progress and are a key revenue component.
- Service revenue (including ion channel programs) — Increased in Q2 2026 due to commencement of new ion channel programs; represents fees for platform services.
- xPloration revenue — Increased on higher instrument sales and related consumables; xPloration is an AI-powered single B-cell screening platform.
Recent performance
Q2 2026 revenue was $13.4M, up from $3.9M in the prior-year quarter, driven by milestone revenue. Net loss narrowed to $5.9M ($0.05 per share) from $15.9M ($0.15 per share) a year earlier. First half 2026 revenue was $27.8M versus $8.1M in 2025. Total costs and operating expenses were flat at $20.1M in Q2. Cash costs and operating expenses were $13.3M in Q2 2026, up from $11.9M in Q2 2025.
Strategy
Management is focusing on expanding its core discovery technologies, particularly the xPloration platform, and targeting ion channel and transporter classes. The company recently added a Chief Operating Officer to strengthen operations. OmniAb is planning an October Investor and Analyst Day to provide business and technology updates.
Risks
- Partner development dependence — Success depends on partners' ability to achieve milestones and commercialize products, over which OmniAb has no control.
- Revenue volatility — Revenue can fluctuate significantly due to timing of milestones and partner program progress, making results hard to predict.
- Historical losses — The company has incurred net losses for several years and may not achieve or sustain profitability.
- Technology acceptance — Commercial success relies on the quality and adoption of its platform by new and existing partners in a competitive market.
Outlook
Management raised full-year 2026 revenue and cash outlook due to continued business momentum. They cite encouraging partner program advancements and expect to leverage core technologies while focusing on xPloration. The company plans to provide further updates at its October Investor and Analyst Day.